17.2 Neoplasia Principles & Tumor Biology

17.2 Neoplasia Principles & Tumor Biology

Quick Answer: Benign = localized, well differentiated; malignant = invade ± metastasize. Multistep hits activate oncogenes (RAS, MYC, BCR-ABL, HER2) and inactivate suppressors (p53, Rb, APC, BRCA…). Grade = histology; stage = spread. Markers and paraneoplastics fingerprint tumors; cachexia is cytokine-driven.

Tumor biology is core multisystem content: every organ system recycles the same principles. CBSE stems mix nomenclature, genetics, grade/stage logic, and paraneoplastic clues—master the framework once and reuse it everywhere.

Benign vs Malignant Features

A neoplasm is a clonal proliferation with partial or complete escape from normal growth control. Behavior distinguishes benign from malignant more than any single microscopic trait.

Benign tumors grow expansively, often with a capsule or clear border, remain localized, and closely resemble the tissue of origin (well differentiated). Mitotic figures are few and normal. They can still kill by location (e.g., meningioma compressing brain, atrial myxoma obstructing flow) or hormone production (adrenal adenoma).

Malignant tumors invade adjacent tissue, destroy architecture, and may metastasize. They show variable differentiation down to anaplasia (loss of differentiation): pleomorphism, hyperchromasia, high N/C ratio, atypical mitoses, loss of polarity. Growth is often rapid with necrosis when vascular supply lags. Metastasis is the definitive malignant property, though not every cancer has metastasized at diagnosis.

Nomenclature

Suffix -oma often denotes a benign tumor (adenoma, lipoma, chondroma, fibroma). Critical malignant exceptions that sound benign: melanoma, lymphoma, mesothelioma, seminoma, and sometimes “hepatoma” used loosely for HCC—prefer precise names.

Carcinoma = epithelial malignancy (adeno-, squamous cell, transitional/urothelial). Sarcoma = mesenchymal malignancy (osteo-, lipo-, leiomyo-, rhabdomyo-). Blastoma = primitive “small round blue cell” tumors of childhood (neuroblastoma, nephroblastoma/Wilms, retinoblastoma). Teratomas contain multiple germ layers; mature ovarian teratoma is usually benign, immature teratoma can be malignant.

Hamartoma is disorganized but mature tissue indigenous to the site (not a true neoplasm in the strict clonal sense for exams, though some are clonal). Choristoma is normal tissue in an abnormal location (heterotopia).

Dysplasia, CIS, Invasion, Metastasis

Dysplasia is disordered growth with cytologic atypia, often in epithelium (cervix, colon polyps, Barrett esophagus). It may be reversible if the driver is removed (e.g., smoking cessation for bronchial dysplasia) but can progress.

Carcinoma in situ (CIS) is full-thickness dysplastic epithelium without basement membrane invasion. Risk of progression is high; treatment is local because metastasis has not occurred.

Invasion breaches the basement membrane into stroma—first step of malignancy for epithelial tumors. Proteases (MMPs), loss of E-cadherin (cell-cell adhesion), and epithelial–mesenchymal transition programs facilitate invasion.

Metastasis routes:

1. Lymphatic — carcinomas commonly to regional nodes first.
2. Hematogenous — sarcomas preferentially; also late carcinomas; liver and lung are common filters; renal cell and hepatocellular invade veins early.
3. Seeding of body cavities — ovarian carcinoma on peritoneum; medulloblastoma via CSF.

Multistep Carcinogenesis

Cancer requires multiple mutations and epigenetic changes accumulated over time. The Vogelstein adenoma–carcinoma sequence in colon is the teaching prototype: APC loss (early adenoma) → KRAS activation → further hits → p53 loss (carcinoma). Field cancerization explains multiple primary tumors in chronically injured mucosa (e.g., smoking airway).

Initiators cause permanent DNA damage; promoters drive proliferation of initiated clones without necessarily being mutagenic alone (hormones, chronic inflammation). Complete carcinogens do both. Viral oncogenesis (HPV E6/E7 → p53/Rb degradation; EBV; HBV/HCV → chronic injury ± viral integration; HTLV-1) and bacterial drivers (H. pylori → gastric adenocarcinoma and MALT lymphoma) are high-yield.

Oncogenes vs Tumor Suppressors

Oncogenes are activated versions of proto-oncogenes; one hit (gain of function) can drive growth. Mechanisms: point mutation, amplification, translocation.

Tumor suppressor genes normally restrain growth or repair DNA; both alleles typically must be lost (two-hit hypothesis). Knudson’s model for retinoblastoma is classic.

DNA Repair Defects

Failure to fix DNA raises mutation rate and cancer risk.

Microsatellite instability-high tumors have distinct morphology and immunotherapy considerations in advanced care, but for CBSE the core is mechanism + organ risk.

Grade vs Stage

Grade evaluates histologic differentiation and mitotic activity (well / moderate / poor / anaplastic, or numeric systems like Gleason for prostate, Nottingham for breast). Higher grade usually means more aggressive biology.

Stage maps anatomic extent: primary tumor size/invasion (T), regional nodes (N), distant metastasis (M)—TNM system. Stage generally predicts prognosis better than grade and guides treatment intensity. Always separate “how ugly under the microscope” (grade) from “how far has it gone” (stage).

Tumor Markers (High-Yield)

Markers aid diagnosis, monitoring, and sometimes screening context—not stand-alone proof of cancer.

Paraneoplastic Syndromes and Cachexia

Paraneoplastic syndromes are remote effects not explained by local invasion or hormones native to the tissue in a physiologic way (or ectopic hormone production).

Cachexia is progressive wasting of fat and muscle out of proportion to simple starvation, driven by TNF-α (cachectin), IL-1, IL-6, and IFN-γ altering metabolism and appetite. It is a major cause of morbidity in advanced cancer and chronic inflammatory disease.

Integration for CBSE Vignettes

Approach: name the process (benign vs malignant; dysplasia vs invasion), then map the molecular hit if given a translocation or inherited syndrome, then use markers/paraneoplastics as tie-breakers. A young patient with countless colon polyps → APC/FAP. MSI colon cancer without polyposis → Lynch/MMR. t(9;22) leukocytosis → BCR-ABL. Squamous lung cancer + high calcium → PTHrP. That layered logic is how multisystem neoplasia items are written.